Loading company
Just reported
Q3 2026 results
From CVRx's results release of November 5, 2026; its quarterly report has since been filed.
Revenue
Actual
$13.8M
-5.8% y/y
-12% q/qGuided
$14M
midpoint
Within guide-1.2%EPS, GAAP
Actual
-$0.52
Guided
—
No guide given
Operating income, GAAP
Actual
-$13M
Guided
—
No guide given
Company outlook
Q4 2026
- Revenue$11.7M – $12.7M-24% y/y First given
Full year 2026
- Revenue$56M – $57M-0.3% y/y Lowered -4.2%
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes CVRx is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Devices
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plc$130BA+
SYKStryker Corp.$121.3BA+
EWEdwards Lifesciences Corporation$60.8BA+
GEHCGE Healthcare Technologies Inc.$37.4BA
GKOSGlaukos Corp$14.6BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now A- EWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
BIIBBiogen Inc.Oct 28, 2026BAGraded B, now A
Built from CVRx, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
